Men don't like how Trump treats the economy. Democrats must cash in on that.
According to new polling, American men are beginning to lose faith in President Donald Trump. It took them long enough, but I'm glad they're here with the rest of us.
A CBS News/YouGov poll showed that the president's approval rating among men had dropped to 47%, while 53% disapproved of the job he was doing. It's a stark contrast from the November election, when Trump won male voters by 55%.
It's a troubling sign for Republicans, but an opportunity for Democrats to gain ground with male voters before 2026. While men tend to go for the GOP, there is a possibility that Trump continues to alienate them by continuing to torpedo the economy and making irrational decisions when it comes to foreign policy and immigration.
Can Democrats fix their messaging?
The big issue for men? How Trump handles the economy.
Men are particularly upset by Trump's handling of the economy.
According to the CBS News/YouGov poll, 49% of men say the economy is getting worse, and 59% disapprove of how he's handling inflation. Sixty percent of men think he's focusing too much on tariffs, while 65% say he isn't doing enough to lower the cost of goods and services.
Opinion: MAGA, I feel bad Trump lied to you about the Epstein list. Who saw this coming?
Democrats, who tend to have weaker messaging on the economy, should take these criticisms and run with them. The cost of tariffs is likely to be passed on to the consumer. The nation's gross domestic product just declined for the first time in three years. Inflation may be cooling, but prices aren't falling.
By putting the blame on Trump for the economic strife Americans are feeling, the Democratic Party could potentially show men that Republican lawmakers may not be the ones to rely on when it comes to their finances. When the rest of us know that was always the case.
Men are also dissatisfied with the conflict in Gaza, and immigration
While 55% of men say the economy and inflation are critical in how they view the president, there are some issues where Trump is also beginning to lose favor.
For example, 53% of men say they are dissatisfied with the Trump administration's handling of the Israel-Hamas war, which the president said he'd end on the campaign trail. Fifty-one percent disapprove of his interactions with Iran. Fifty percent of men disapprove of how Trump is handling immigration, with 47% saying the administration is deporting more immigrants than they believed it would, according to that same poll.
All of these concerns are corroborated by other polls that show Trump is widely disliked.
This should be a wake-up call that Democrats need to strengthen their message on the Israel-Hamas war, at least advocating for peace talks.
They could also combine immigration with economic issues, and stress how Trump's deportation agenda could negatively affect the GDP and increase the cost of food.
Opinion: Trump keeps brutalizing immigrants because he's failing at everything else
Gen Z is particularly unhappy
Generation Z, born between 1997 to 2012, also seems to have woken up to Trump's failures.
The CBS News/YouGov poll found that his approval rating among 18- to 29-year-olds plummeted to 28% in July. Seventy-one percent of those under 30 disapprove of Trump's handling of the economy, and 73% disapprove of how he's handling inflation.
As with men, it's a far cry from how Gen Z felt about Trump in the 2024 election, when voters ages 18-29 supported Democratic presidential nominee Kamala Harris by a much smaller margin than they supported former President Joe Biden in 2020.
Among this age group, 56% of males voted for Trump, 1 percentage point more than among all male voters.
Opinion: Trump is unpopular, polls show, and he's building an America most Americans hate
It's telling that the generation whose perception of the Republican Party is entirely shaped by the rise of Trump is suddenly souring on him. Perhaps people around my age are finally realizing that targeting marginalized communities won't actually improve their quality of life, or that Trump made promises he couldn't keep.
They might also be realizing that the positive emotions they felt during the first Trump administration can be chalked up to childhood nostalgia.
For those of us in the generation who were old enough to vote in 2016, the negatives of Trump's first presidency were unavoidable.
Opinion alerts: Get columns from your favorite columnists + expert analysis on top issues, delivered straight to your device through the USA TODAY app. Don't have the app? Download it for free from your app store.
If the Democrats are clever, they'll consider this polling and begin brainstorming ways to further drive a wedge between Trump and male voters, particularly those in Gen Z. Yet I'm not sure Democrats are prepared to pick up the young voters Republicans are siphoning off. Their solution now seems to be doing nothing – Democratic leadership essentially disappeared after the 2024 election, and no one seems to know how to get the party back on track.
Ahead of the 2026 midterm elections, they need to focus on more than podcasts and memes. They need to be working on crafting a populist message and focusing on economic issues, because that seems to be the deciding factor in whether or not a president is doing well.
Follow USA TODAY columnist Sara Pequeño on X, formerly Twitter: @sara__pequeno
You can read diverse opinions from our USA TODAY columnists and other writers on the Opinion front page, on X, formerly Twitter, @usatodayopinion and in our Opinion newsletter.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
Super Micro (SMCI) Rallies 10.2% as US Freezes Export Curbs to China
We recently published . Super Micro Computer, Inc. (NASDAQ:SMCI) is one of the best-performing stocks on Monday. Super Micro jumped for a fourth straight day on Monday, adding 10.24 percent to close at $60.05 apiece as investors cheered President Donald Trump's decision to freeze export restrictions on technology products to China as Washington and Beijing resume trade negotiations. The US and China will meet in Stockholm for a third round of trade talks on Monday, following previous meetings in Geneva and London. Known for its AI-focused server systems, Super Micro Computer, Inc. (NASDAQ:SMCI) is one of the companies benefiting from increased technology spending this year. Year-to-date, its stock has gone up by almost 100 percent as more companies globally build large artificial intelligence workloads. Copyright: wavebreakmediamicro / 123RF Stock Photo In other developments, Super Micro Computer, Inc. (NASDAQ:SMCI) is set to announce the results of its earnings performance for the fourth quarter of fiscal year 2025 after market close on August 5. An investor call will be held on the same day to elaborate on the results. While we acknowledge the potential of SMCI as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Sign in to access your portfolio
Yahoo
15 minutes ago
- Yahoo
Patterson-UTI (PTEN) Jumps on Bargain-Hunting, Dividend Distribution
We recently published . Patterson-UTI Energy, Inc. (NASDAQ:PTEN) is one of the best-performing stocks on Monday. Patterson-UTI bounced back by 5.41 percent on Monday to close at $6.24 apiece as investors loaded up positions following a two-day drop dragged by dismal earnings performance. During the period, Patterson-UTI Energy, Inc. (NASDAQ:PTEN) said it swung to a net loss attributable to shareholders of $49 million from an $11 million net income in the same period last year, as revenues dropped by 7 percent to $1.2 billion from $1.3 billion year-on-year. The performance was largely dampened by increasing oil market volatility during the quarter, driven by evolving trade policies, among others. For the six-month figure, Patterson-UTI Energy, Inc. (NASDAQ:PTEN) also reversed a $62-million net income attributable to shareholders last year after booking a $48-million net loss in the first half of the year. Revenues were lower by 10.7 percent to $2.5 billion from $2.8 billion year-on-year. Patterson-UTI Energy, Inc. (NASDAQ:PTEN) also declared a $0.08 dividend to shareholders as of September 2, payable on September 15. While we acknowledge the potential of PTEN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Sign in to access your portfolio
Yahoo
15 minutes ago
- Yahoo
Stock market today: S&P 500, Nasdaq rise as earnings flood in, jobs data on deck
US stocks moved higher on Tuesday, eyeing a bid for more records as investors combed through a fresh rush of corporate earnings and waited for key economic data in a big week on Wall Street. The S&P 500 (^GSPC) rose 0.2% on the heels of narrowly notching a sixth all-time closing high in a row, while the tech-heavy Nasdaq Composite (^IXIC) led the way higher with a 0.4% gain. The Dow Jones Industrial Average (^DJI) was roughly flat. The mood is modestly upbeat as a blockbuster week for markets gets into full swing. The Federal Reserve kicks off its two-day policy meeting on Tuesday, while the JOLTS job openings update for June due later ushers in a series of crucial labor data culminating in Friday's nonfarm payrolls report. Meanwhile, earnings take center stage as before-the-bell reports from Spotify (SPOT), Merck (MRK), and UnitedHealth (UNH) disappointed Wall Street. Some news were better than others: Boeing (BA) shares lifted as the world's largest planemaker's quarterly results topped expectations. After the bell Tuesday, Starbucks (SBUX) earnings will be scrutinized for signs of turnaround progress and of the impact of tariffs. The wave of earnings Tuesday will help set the tone for this week's highlights: results from tech giants Apple (AAPL), Amazon (AMZN), Microsoft (MSFT), and Meta (META). Read more: Full earnings coverage in our live blog Also looming large is President Trump's deadline Friday for trading partners to strike deals or face blanket tariff rates. The Commerce Department's Census Bureau on Tuesday reported a sharp decline in the US goods trade deficit in June as businesses looked to get ahead of tariffs. Hopes for an extension to the US-China trade truce are buoying the likes of AI chipmaker Nvidia's (NVDA) stock. Read more: The latest on Trump's tariffs Trade war fears may have lost their grip on markets, given the S&P 500 (^GSPC) and Nasdaq Composite (^IXIC) only barely managed new records on Monday despite a new US-EU trade deal. On Tuesday's economic docket, Conference Board's July reading on consumer confidence and a S&P CoreLogic print on home prices in May provide a health check on the economy ahead of an update on second quarter GDP later this week, P&G dips as it warns of $1 billion tariff hit Procter & Gamble (PG) stock dipped about 1%, reversing a slight premarket gain, as the company took a cautious approach with its financial outlook while it navigates uncertain consumer sentiment and Trump's tariffs. Yahoo Finance's Brian Sozzi reports: Read the full story here. Tech leads stocks higher at the open The tech-heavy Nasdaq Composite (^IXIC) led US stocks higher at the open on Tuesday morning with a 0.5% gain. Meanwhile, the S&P 500 (^GSPC) rose 0.2% on the heels of notching a sixth all-time closing high in a row on Monday. The Dow Jones Industrial Average (^DJI) opened roughly flat. Investors are digesting a wave of earnings reports and US trade data showing a sharp narrowing in the deficit (as tariffs loom). Meanwhile, they are looking ahead to the JOLTS job openings update for June at 10 a.m. ET. for labor market insight. Major drugmakers mixed amid earnings Of the notable drugmakers reporting earnings Tuesday, AstraZeneca rose almost 2% and Merck fell nearly 4% before the market open. British drugmaker AstraZeneca reported second quarter revenue ahead of expectations Tuesday, with its cancer drugs helping fuel sales for the period. Meanwhile, fellow pharma giant Merck reported earnings below Wall Street's projections, according to Bloomberg consensus data, and revenue from its HPV vaccine Gardasil was also less than expected amid continued headwinds in China. Investors are also bracing for patents for its drug Keytruda (which accounted for roughly half of its second quarter revenue) to expire in 2028. Also on Tuesday, Danish drugmaker Novo Nordisk (NVO) plummeted roughly 20%. The firm cut its 2025 revenue and profit outlook, pointing to lower than expected sales growth of its obesity drug Wegovy in the US, ahead of its second quarter earnings results slated for Aug. 6. Trump's DOJ puts companies on notice: Don't evade tariffs The Justice Department is putting American companies on notice that they could be prosecuted if they chose to evade President Trump's tariffs, even as the legality of the president's "Liberation Day" duties remain unsettled in US courts. Yahoo Finance's Alexis Keenan reports: Read more here. Nvidia leads Mag 7 higher on sign of 'enormous pent-up demand' from China Nvidia (NVDA) led the Big Tech "Magnificent Seven" stocks higher on Tuesday before the market open, climbing 1.4%. The gain came after Reuters reported that the AI chipmaker had ordered 300,000 H20 chips from its contract manufacturer TSMC. "This supports our theory that there is enormous pent-up demand for NVDA chips from China right now," Hedgeye Risk Management analyst Felix Wang wrote in a note to clients. Meanwhile, Microsoft (MSFT), Meta (META), and Amazon (AMZN) rose fractionally ahead of their quarterly earnings reports later this week. Apple (AAPL), Google (GOOG), and Tesla (TSLA) traded down less than 1%. Good morning. Here's what's happening today. Economic data: S&P CoreLogic 20-city home price index (May); Conference Board consumer confidence, July; Job Openings and Labor Turnover Survey (June); Dallas Fed services activity (July) Earnings: Boeing (BA), Booking Holdings (BKNG), Caesars (CZR), Cheesecake Factory (CAKE), Merck (MRK), PayPal (PYPL), Procter & Gamble (PG), Spotify (SPOT), Starbucks (SBUX), SoFi (SOFI), UnitedHealth Group (UNH), UPS (UPS), Visa (V) Here are some of the biggest stories you may have missed overnight and early this morning: The market is finally getting what it wants 35 charts explain markets and the economy right now UnitedHealth stock falls after reporting mixed Q2 earnings Sarepta stock soars as FDA reverses course on gene therapy pause Spotify stock slides after Q2 earnings and revenue miss Trump's DOJ puts companies on notice on tariffs US, EU rush to clinch final details and lock in trade deal Apple to Shutter a Retail Store in China for the First Time Ever Stellantis faces $1.7B hit from US tariffs this year Trending tickers: UPS, Whilepool and Royal Caribbean Here are some top stocks trending on Yahoo Finance in premarket trading: UPS (UPS) stock fell over 2% before the bell on Tuesday after reporting a drop in second-quarter profit and revenue, as demand took a hit from new "de minimis" tariffs on low-value Chinese shipments and mounting risks from President Donald Trump's trade policies. Whirlpool (WHR) stock fell premarket on Tuesday. after the appliance maker slashed its earnings outlook the day prior. Royal Caribbean (RCL) stock rose 4% before the bell after raising its annual profit forecast on Tuesday, banking on resilient demand for the cruise operator's high-end private island destinations and premium sailings. The market is finally getting what it wants Wall Street's busiest week of the summer is turning out to be an inflection point. Yahoo Finance's Hamza Shaban explains why in today's Morning Brief: Read more here. Spotify stock sinks after Q2 earnings miss Spotify (SPOT) shares fell as much as 10% in early premarket trading Tuesday after the company missed second quarter earnings and revenue expectations. The results follow a remarkable 120% rally over the past year, as the stock rebounded from 2022 lows on the back of price hikes, cost cuts, and investor enthusiasm for AI and advertising. Spotify hit a record high of $738.45 earlier this month, but shares slid to around $635 immediately following the results. Spotify reported second quarter revenue of €4.19 billion ($4.86 billion), missing analyst expectations of €4.27 billion, though up from €3.81 billion in the same period last year. The company posted an adjusted loss of €0.42 ($0.49) per share, sharply missing forecasts for a profit of €1.97 and down from earnings of €1.33 in Q2 2024. "Outsized currency movements during the quarter impacted reported revenue by €104 million vs. guidance," the company said in the earnings release. Operating income also fell short of expectations in the quarter, though subscriber metrics for both premium and ad-supported tiers came in ahead of estimates. Gross margins of 31.5% came in as expected. Spotify's massive rally heading into the earnings report was fueled by a sweeping business overhaul, including layoffs, leadership changes, and a pullback from costly podcast exclusivity. After spending $1 billion to build out its podcast business, the company has since scaled back and narrowed its focus. Still, it remains committed to the medium, paying over $100 million to creators in Q1 alone, including high-profile names like Joe Rogan and Alex Cooper. Read more here. UnitedHealth stock slips after mixed Q2 results Shares of UnitedHealth Group (UNH) fell nearly 3% after its quarterly results before the bell painted a mixed picture. Yahoo Finance's Anjalee Khemlani reports: Read more here. Sarepta stock rockets higher after FDA greenlight Shares in drugmaker Sarepta (SRPT) rocketed up over 30% in premarket after the embattled company got the FDA's go-ahead to resume shipments of its Elevdis gene therapy. The greenlight comes after Sarepta put a voluntary pause on shipments for some patients while the US regulator reviewed its safety following deaths. The FDA on Monday recommended that the compa lift that halt. Sarepta's stock is poised to build on a 16% gain on Monday, continuing a recent volatile spell triggered by changing fortunes for its best-selling product. AP reports: Read more here. Nvidia orders 300,000 H20 chips from TSMC to satiate Chinese demand Reuters reports: Nvidia placed orders for 300,000 H20 chipsets with contract manufacturer TSMC last week, two sources said, with one of them adding that strong Chinese demand had led the U.S. firm to change its mind about just relying on its existing stockpile. Read more here. Oil maintains gains with tariffs and OPEC+ supply in sight Oil maintained gains following Trump putting pressure on Russia over the war in Ukraine with economic sanctions against Putin's government on the table. Bloomberg reports: Read more here. P&G dips as it warns of $1 billion tariff hit Procter & Gamble (PG) stock dipped about 1%, reversing a slight premarket gain, as the company took a cautious approach with its financial outlook while it navigates uncertain consumer sentiment and Trump's tariffs. Yahoo Finance's Brian Sozzi reports: Read the full story here. Procter & Gamble (PG) stock dipped about 1%, reversing a slight premarket gain, as the company took a cautious approach with its financial outlook while it navigates uncertain consumer sentiment and Trump's tariffs. Yahoo Finance's Brian Sozzi reports: Read the full story here. Tech leads stocks higher at the open The tech-heavy Nasdaq Composite (^IXIC) led US stocks higher at the open on Tuesday morning with a 0.5% gain. Meanwhile, the S&P 500 (^GSPC) rose 0.2% on the heels of notching a sixth all-time closing high in a row on Monday. The Dow Jones Industrial Average (^DJI) opened roughly flat. Investors are digesting a wave of earnings reports and US trade data showing a sharp narrowing in the deficit (as tariffs loom). Meanwhile, they are looking ahead to the JOLTS job openings update for June at 10 a.m. ET. for labor market insight. The tech-heavy Nasdaq Composite (^IXIC) led US stocks higher at the open on Tuesday morning with a 0.5% gain. Meanwhile, the S&P 500 (^GSPC) rose 0.2% on the heels of notching a sixth all-time closing high in a row on Monday. The Dow Jones Industrial Average (^DJI) opened roughly flat. Investors are digesting a wave of earnings reports and US trade data showing a sharp narrowing in the deficit (as tariffs loom). Meanwhile, they are looking ahead to the JOLTS job openings update for June at 10 a.m. ET. for labor market insight. Major drugmakers mixed amid earnings Of the notable drugmakers reporting earnings Tuesday, AstraZeneca rose almost 2% and Merck fell nearly 4% before the market open. British drugmaker AstraZeneca reported second quarter revenue ahead of expectations Tuesday, with its cancer drugs helping fuel sales for the period. Meanwhile, fellow pharma giant Merck reported earnings below Wall Street's projections, according to Bloomberg consensus data, and revenue from its HPV vaccine Gardasil was also less than expected amid continued headwinds in China. Investors are also bracing for patents for its drug Keytruda (which accounted for roughly half of its second quarter revenue) to expire in 2028. Also on Tuesday, Danish drugmaker Novo Nordisk (NVO) plummeted roughly 20%. The firm cut its 2025 revenue and profit outlook, pointing to lower than expected sales growth of its obesity drug Wegovy in the US, ahead of its second quarter earnings results slated for Aug. 6. Of the notable drugmakers reporting earnings Tuesday, AstraZeneca rose almost 2% and Merck fell nearly 4% before the market open. British drugmaker AstraZeneca reported second quarter revenue ahead of expectations Tuesday, with its cancer drugs helping fuel sales for the period. Meanwhile, fellow pharma giant Merck reported earnings below Wall Street's projections, according to Bloomberg consensus data, and revenue from its HPV vaccine Gardasil was also less than expected amid continued headwinds in China. Investors are also bracing for patents for its drug Keytruda (which accounted for roughly half of its second quarter revenue) to expire in 2028. Also on Tuesday, Danish drugmaker Novo Nordisk (NVO) plummeted roughly 20%. The firm cut its 2025 revenue and profit outlook, pointing to lower than expected sales growth of its obesity drug Wegovy in the US, ahead of its second quarter earnings results slated for Aug. 6. Trump's DOJ puts companies on notice: Don't evade tariffs The Justice Department is putting American companies on notice that they could be prosecuted if they chose to evade President Trump's tariffs, even as the legality of the president's "Liberation Day" duties remain unsettled in US courts. Yahoo Finance's Alexis Keenan reports: Read more here. The Justice Department is putting American companies on notice that they could be prosecuted if they chose to evade President Trump's tariffs, even as the legality of the president's "Liberation Day" duties remain unsettled in US courts. Yahoo Finance's Alexis Keenan reports: Read more here. Nvidia leads Mag 7 higher on sign of 'enormous pent-up demand' from China Nvidia (NVDA) led the Big Tech "Magnificent Seven" stocks higher on Tuesday before the market open, climbing 1.4%. The gain came after Reuters reported that the AI chipmaker had ordered 300,000 H20 chips from its contract manufacturer TSMC. "This supports our theory that there is enormous pent-up demand for NVDA chips from China right now," Hedgeye Risk Management analyst Felix Wang wrote in a note to clients. Meanwhile, Microsoft (MSFT), Meta (META), and Amazon (AMZN) rose fractionally ahead of their quarterly earnings reports later this week. Apple (AAPL), Google (GOOG), and Tesla (TSLA) traded down less than 1%. Nvidia (NVDA) led the Big Tech "Magnificent Seven" stocks higher on Tuesday before the market open, climbing 1.4%. The gain came after Reuters reported that the AI chipmaker had ordered 300,000 H20 chips from its contract manufacturer TSMC. "This supports our theory that there is enormous pent-up demand for NVDA chips from China right now," Hedgeye Risk Management analyst Felix Wang wrote in a note to clients. Meanwhile, Microsoft (MSFT), Meta (META), and Amazon (AMZN) rose fractionally ahead of their quarterly earnings reports later this week. Apple (AAPL), Google (GOOG), and Tesla (TSLA) traded down less than 1%. Good morning. Here's what's happening today. Economic data: S&P CoreLogic 20-city home price index (May); Conference Board consumer confidence, July; Job Openings and Labor Turnover Survey (June); Dallas Fed services activity (July) Earnings: Boeing (BA), Booking Holdings (BKNG), Caesars (CZR), Cheesecake Factory (CAKE), Merck (MRK), PayPal (PYPL), Procter & Gamble (PG), Spotify (SPOT), Starbucks (SBUX), SoFi (SOFI), UnitedHealth Group (UNH), UPS (UPS), Visa (V) Here are some of the biggest stories you may have missed overnight and early this morning: The market is finally getting what it wants 35 charts explain markets and the economy right now UnitedHealth stock falls after reporting mixed Q2 earnings Sarepta stock soars as FDA reverses course on gene therapy pause Spotify stock slides after Q2 earnings and revenue miss Trump's DOJ puts companies on notice on tariffs US, EU rush to clinch final details and lock in trade deal Apple to Shutter a Retail Store in China for the First Time Ever Stellantis faces $1.7B hit from US tariffs this year Economic data: S&P CoreLogic 20-city home price index (May); Conference Board consumer confidence, July; Job Openings and Labor Turnover Survey (June); Dallas Fed services activity (July) Earnings: Boeing (BA), Booking Holdings (BKNG), Caesars (CZR), Cheesecake Factory (CAKE), Merck (MRK), PayPal (PYPL), Procter & Gamble (PG), Spotify (SPOT), Starbucks (SBUX), SoFi (SOFI), UnitedHealth Group (UNH), UPS (UPS), Visa (V) Here are some of the biggest stories you may have missed overnight and early this morning: The market is finally getting what it wants 35 charts explain markets and the economy right now UnitedHealth stock falls after reporting mixed Q2 earnings Sarepta stock soars as FDA reverses course on gene therapy pause Spotify stock slides after Q2 earnings and revenue miss Trump's DOJ puts companies on notice on tariffs US, EU rush to clinch final details and lock in trade deal Apple to Shutter a Retail Store in China for the First Time Ever Stellantis faces $1.7B hit from US tariffs this year Trending tickers: UPS, Whilepool and Royal Caribbean Here are some top stocks trending on Yahoo Finance in premarket trading: UPS (UPS) stock fell over 2% before the bell on Tuesday after reporting a drop in second-quarter profit and revenue, as demand took a hit from new "de minimis" tariffs on low-value Chinese shipments and mounting risks from President Donald Trump's trade policies. Whirlpool (WHR) stock fell premarket on Tuesday. after the appliance maker slashed its earnings outlook the day prior. Royal Caribbean (RCL) stock rose 4% before the bell after raising its annual profit forecast on Tuesday, banking on resilient demand for the cruise operator's high-end private island destinations and premium sailings. Here are some top stocks trending on Yahoo Finance in premarket trading: UPS (UPS) stock fell over 2% before the bell on Tuesday after reporting a drop in second-quarter profit and revenue, as demand took a hit from new "de minimis" tariffs on low-value Chinese shipments and mounting risks from President Donald Trump's trade policies. Whirlpool (WHR) stock fell premarket on Tuesday. after the appliance maker slashed its earnings outlook the day prior. Royal Caribbean (RCL) stock rose 4% before the bell after raising its annual profit forecast on Tuesday, banking on resilient demand for the cruise operator's high-end private island destinations and premium sailings. The market is finally getting what it wants Wall Street's busiest week of the summer is turning out to be an inflection point. Yahoo Finance's Hamza Shaban explains why in today's Morning Brief: Read more here. Wall Street's busiest week of the summer is turning out to be an inflection point. Yahoo Finance's Hamza Shaban explains why in today's Morning Brief: Read more here. Spotify stock sinks after Q2 earnings miss Spotify (SPOT) shares fell as much as 10% in early premarket trading Tuesday after the company missed second quarter earnings and revenue expectations. The results follow a remarkable 120% rally over the past year, as the stock rebounded from 2022 lows on the back of price hikes, cost cuts, and investor enthusiasm for AI and advertising. Spotify hit a record high of $738.45 earlier this month, but shares slid to around $635 immediately following the results. Spotify reported second quarter revenue of €4.19 billion ($4.86 billion), missing analyst expectations of €4.27 billion, though up from €3.81 billion in the same period last year. The company posted an adjusted loss of €0.42 ($0.49) per share, sharply missing forecasts for a profit of €1.97 and down from earnings of €1.33 in Q2 2024. "Outsized currency movements during the quarter impacted reported revenue by €104 million vs. guidance," the company said in the earnings release. Operating income also fell short of expectations in the quarter, though subscriber metrics for both premium and ad-supported tiers came in ahead of estimates. Gross margins of 31.5% came in as expected. Spotify's massive rally heading into the earnings report was fueled by a sweeping business overhaul, including layoffs, leadership changes, and a pullback from costly podcast exclusivity. After spending $1 billion to build out its podcast business, the company has since scaled back and narrowed its focus. Still, it remains committed to the medium, paying over $100 million to creators in Q1 alone, including high-profile names like Joe Rogan and Alex Cooper. Read more here. Spotify (SPOT) shares fell as much as 10% in early premarket trading Tuesday after the company missed second quarter earnings and revenue expectations. The results follow a remarkable 120% rally over the past year, as the stock rebounded from 2022 lows on the back of price hikes, cost cuts, and investor enthusiasm for AI and advertising. Spotify hit a record high of $738.45 earlier this month, but shares slid to around $635 immediately following the results. Spotify reported second quarter revenue of €4.19 billion ($4.86 billion), missing analyst expectations of €4.27 billion, though up from €3.81 billion in the same period last year. The company posted an adjusted loss of €0.42 ($0.49) per share, sharply missing forecasts for a profit of €1.97 and down from earnings of €1.33 in Q2 2024. "Outsized currency movements during the quarter impacted reported revenue by €104 million vs. guidance," the company said in the earnings release. Operating income also fell short of expectations in the quarter, though subscriber metrics for both premium and ad-supported tiers came in ahead of estimates. Gross margins of 31.5% came in as expected. Spotify's massive rally heading into the earnings report was fueled by a sweeping business overhaul, including layoffs, leadership changes, and a pullback from costly podcast exclusivity. After spending $1 billion to build out its podcast business, the company has since scaled back and narrowed its focus. Still, it remains committed to the medium, paying over $100 million to creators in Q1 alone, including high-profile names like Joe Rogan and Alex Cooper. Read more here. UnitedHealth stock slips after mixed Q2 results Shares of UnitedHealth Group (UNH) fell nearly 3% after its quarterly results before the bell painted a mixed picture. Yahoo Finance's Anjalee Khemlani reports: Read more here. Shares of UnitedHealth Group (UNH) fell nearly 3% after its quarterly results before the bell painted a mixed picture. Yahoo Finance's Anjalee Khemlani reports: Read more here. Sarepta stock rockets higher after FDA greenlight Shares in drugmaker Sarepta (SRPT) rocketed up over 30% in premarket after the embattled company got the FDA's go-ahead to resume shipments of its Elevdis gene therapy. The greenlight comes after Sarepta put a voluntary pause on shipments for some patients while the US regulator reviewed its safety following deaths. The FDA on Monday recommended that the compa lift that halt. Sarepta's stock is poised to build on a 16% gain on Monday, continuing a recent volatile spell triggered by changing fortunes for its best-selling product. AP reports: Read more here. Shares in drugmaker Sarepta (SRPT) rocketed up over 30% in premarket after the embattled company got the FDA's go-ahead to resume shipments of its Elevdis gene therapy. The greenlight comes after Sarepta put a voluntary pause on shipments for some patients while the US regulator reviewed its safety following deaths. The FDA on Monday recommended that the compa lift that halt. Sarepta's stock is poised to build on a 16% gain on Monday, continuing a recent volatile spell triggered by changing fortunes for its best-selling product. AP reports: Read more here. Nvidia orders 300,000 H20 chips from TSMC to satiate Chinese demand Reuters reports: Nvidia placed orders for 300,000 H20 chipsets with contract manufacturer TSMC last week, two sources said, with one of them adding that strong Chinese demand had led the U.S. firm to change its mind about just relying on its existing stockpile. Read more here. Reuters reports: Nvidia placed orders for 300,000 H20 chipsets with contract manufacturer TSMC last week, two sources said, with one of them adding that strong Chinese demand had led the U.S. firm to change its mind about just relying on its existing stockpile. Read more here. Oil maintains gains with tariffs and OPEC+ supply in sight Oil maintained gains following Trump putting pressure on Russia over the war in Ukraine with economic sanctions against Putin's government on the table. Bloomberg reports: Read more here. Oil maintained gains following Trump putting pressure on Russia over the war in Ukraine with economic sanctions against Putin's government on the table. Bloomberg reports: Read more here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data